fulvestrant has been researched along with alpha-aminopyridine in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 28 (40.00) | 24.3611 |
| 2020's | 42 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crowder, RJ; Ellis, MJ; Gao, F; Guintoli, T; Lin, L; Ma, CX; Phommaly, C; Sanchez, CG | 1 |
| Kimura-Tsuchiya, R; Saji, S; Sasaki, E | 1 |
| Ademuyiwa, F; Ellis, MJ; Griffith, M; Griffith, OL; Guo, Z; Han, J; Hoog, J; Lockhart, C; Luo, J; Ma, CX; Mardis, E; Nagaraj, G; Naughton, M; Pluard, T; Ramu, A; Skidmore, ZL; Spies, NC; Suresh, R; Thomas, S; Trani, L | 1 |
| Lücking, U; Sirvent, JA | 1 |
| Arteaga, CL; Awada, A; Baselga, J; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; Dharan, B; Di Tomaso, E; Hachemi, S; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Massacesi, C; Masuda, N; Pistilli, B; Takahashi, M; Tseng, LM; Urban, P; Vuylsteke, P | 1 |
| Barriga, S; Bourayou, N; Burdaeva, O; Frenzel, M; Grischke, EM; Inoue, K; Kaufman, PA; Koh, H; Lin, Y; Llombart-Cussac, A; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Smith, IC; Sohn, J; Toi, M | 1 |
| Griggs, JJ; Wolff, AC | 1 |
| Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B | 1 |
| Chen, S; Huang, TT; Liu, CY; Petrossian, K; Tseng, LM; Wu, CY | 1 |
| Messina, C; Messina, M; Zanardi, E | 1 |
| Kim, ES | 1 |
| Bachelot, T; Blau, S; Bordonaro, R; Ciruelos, E; Csőszi, T; Decker, T; Dharan, B; Di Leo, A; Egle, D; El-Hashimy, M; Janni, W; Johnston, S; Kalev, D; Lee, KS; Lønning, PE; Mouret-Reynier, MA; O'Regan, R; Schirone, A; Sellami, D; Tjan-Heijnen, VCG; Weber, D | 1 |
| Kotake, T; Toi, M | 1 |
| Gonçalves, A | 1 |
| Abdel-Razeq, H | 1 |
| Beck, JT; Bianchi, GV; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Esteva, FJ; Fasching, PA; Im, SA; Jerusalem, G; Martín, M; Miller, M; Neven, P; Nusch, A; Petrakova, K; Pivot, X; Rodriguez Lorenc, K; Slamon, DJ; Sonke, GS; Taran, T; Vidam, G; Wang, Y | 1 |
| Arteaga, CL; Awada, A; Baselga, J; Bourdeau, L; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; El-Hashimy, M; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Le Mouhaër, S; Masuda, N; Pistilli, B; Sankaran, B; Sellami, D; Tseng, LM | 1 |
| Huang, HW; Huang, LS; Li, XY; Lin, JZ; Wang, HB; Xu, QN | 1 |
| Arteaga, CL; Balko, JM; Bardia, A; Bauer, JA; Behdad, A; Cristofanilli, M; Croessmann, S; Cruz, MR; Dugger, TC; Ericsson, PG; Formisano, L; Guerrero-Zotano, AL; Guo, Y; Hanker, AB; He, W; Jansen, VM; Lanman, RB; Lee, KM; Lu, Y; Mayer, IA; Miller, M; Nagy, RJ; Nixon, MJ; O'Shaughnessy, J; Sanders, ME; Schwarz, LJ; Servetto, A; Shyr, Y; Solovieff, N; Su, F; Sudhan, DR | 1 |
| Chen, Q; Dai, Y; Guo, Q; Lin, X; Xu, R; Ye, L; Zhang, Y | 1 |
| Cai, Z; Enatsu, S; Ishiguro, H; Omori, Y | 1 |
| Yardley, DA | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Barriga, S; Burdaeva, O; Conte, P; Frenzel, M; Grischke, EM; Hurt, K; Inoue, K; Johnston, S; Kaufman, PA; Koh, H; Llombart-Cussac, A; Lu, Y; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Sohn, J; Toi, M | 1 |
| Stirrups, R | 1 |
| Killock, D | 1 |
| Tamura, K | 1 |
| Beck, JT; Bianchi, GV; Chakravartty, A; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Esteva, FJ; Fasching, PA; Im, SA; Jerusalem, G; Martín, M; Neven, P; Nusch, A; Petrakova, K; Pivot, X; Rodriguez-Lorenc, K; Slamon, DJ; Sondhi, M; Sonke, GS; Taran, T; Wang, Y | 1 |
| Andre, V; Carter, GC; Grischke, EM; Kaufman, PA; Neven, P; Price, GL; Shekarriz, S; Sledge, GW; Sohn, J; Stoffregen, C; Toi, M | 1 |
| Buisseret, L; de Azambuja, E; Eiger, D; Nogueira, MS; Pondé, NF; Wagner, M | 1 |
| André, F; Catron, K; Chan, A; Chapman, SC; Gainford, MC; Goel, S; Hilton, JF; Im, SA; Johnston, SR; Kim, SB; Price, GL; Ricci, F; Tolaney, SM; Troso-Sandoval, TA; Wardley, AM; Yang, Z; Zambelli, S | 1 |
| Battisti, NML; Ring, A | 1 |
| Briceño-Casado, MDP; Fénix-Caballero, S; Gil-Sierra, MD | 1 |
| Kim, DH; Sun, R; Wei, LJ | 1 |
| Frenzel, M; Sledge, GW | 1 |
| Hindié, E | 1 |
| Jerusalem, G; Slamon, DJ | 1 |
| Firenze, A; Gebbia, V; Valerio, MR; Vigneri, P | 1 |
| Ameye, L; Awada, A; Azambuja, E; Brandão, M; Caparica, R; De Angelis, C; Desmedt, C; Di Cosimo, S; Eiger, D; Franzoi, MA; Kotecki, N; Lambertini, M; Piccart, M; Ponde, N | 1 |
| Abdelhady, AM; Bachelot, T; Calvo, E; Fasolo, A; Forero-Torres, A; Hamilton, E; Im, YH; Lee, SC; Lu, YS; Maur, M; Nardi, L; Ruan, S; Stammberger, U; Tiedt, R; Tolaney, SM | 1 |
| Andre, VAM; Barriga, S; Cox, J; García-Sáenz, JA; Goetz, M; Huober, J; Masuda, N; Rugo, HS; Sohn, JH | 1 |
| Beck, JT; Bianchi, GV; Chan, A; Chandiwana, D; De Laurentiis, M; Esteva, FJ; Fasching, PA; Jerusalem, G; Lanoue, B; Martin, M; Neven, P; Nusch, A; Pivot, X; Ridolfi, A; Rodriguez Lorenc, K; Wang, Y | 1 |
| Jerusalem, G; Neven, P; Sonke, GS | 1 |
| André, VAM; Campone, M; Chouaki, N; Goetz, MP; Grischke, EM; Manso, L; Okera, M; San Antonio, B; Sledge, GW; Toi, M; Wildiers, H | 1 |
| Akiyama, Y; Doi, S; Hagihara, K; Matsushita, K; Motoki, Y; Nakaguchi, K; Sakisaka, H | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK | 1 |
| Inoue, K; Ito, Y; Iwata, H; Kawaguchi, T; Llombart-Cussac, A; Masuda, N; Miyoshi, Y; Mori, J; Mukai, H; Nakayama, T; Sakaguchi, S; Sledge, GW; Takahashi, M; Tanizawa, Y; Toi, M; van der Walt, JS | 1 |
| Kudo, S; Makino, T; Tanaka, T; Umetsu, R | 1 |
| Gallagher, P; Haynes, HR; Mohan, V; Mozayani, B | 1 |
| Abe, M; Chiba, R; Ishiguro, A; Ito, K; Kato, H; Kubota, R; Matsunami, O; Narita, Y; Ohigashi, A; Tanimoto, A | 1 |
| Beck, JT; Chakravartty, A; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Deore, U; Fasching, PA; Im, S; Jerusalem, G; Ji, Y; Martín, M; Neven, P; Nusch, A; Petrakova, K; Slamon, DJ; Sonke, GS; Taran, T; Valeria Bianchi, G; Wang, C; Zarate, JP | 1 |
| Chandiwana, D; Delea, TE; Park, J; Stellato, D; Thabane, ME | 1 |
| Burdaeva, O; Conte, P; Grischke, EM; Haddad, N; Hurt, KC; Inoue, K; Johnston, SRD; Kaufman, PA; Koh, H; Llombart-Cussac, A; Lu, Y; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Sohn, J; Toi, M | 1 |
| Goetz, MP; Haddad, N; Hurt, KC; Iwata, H; Kaufman, PA; Lu, Y; Neven, P; Rugo, HS; Sledge, GW; Toi, M; Tolaney, SM | 1 |
| Cheng, MY; Gao, HF; Ji, F; Li, JQ; Niu, G; Wang, K; Yang, CQ; Yang, M; Zhang, JS; Zhang, LL; Zhang, QZ; Zhu, T | 1 |
| Lagampan, C; Parinyanitikul, N; Poovorawan, N | 1 |
| Beck, JT; Chan, A; Chandiwana, D; De Laurentiis, M; Delea, TE; Fasching, PA; Im, SA; Jerusalem, G; Lanoue, B; Lonshteyn, A; Martin, M; Neven, P; Nusch, A | 1 |
| Grischke, EM; Jansen, VM; Litchfield, LM; Llombart-Cussac, A; Neven, P; Sledge, GW; Sohn, J; Soliman, H; Toi, M; Tolaney, SM; Wang, H; Wijayawardana, S | 1 |
| Çelik, H; Çil, T; Duman, BB; Erçolak, V; Eser, K; İnal, A; Kesen, O; Köşeci, T; Önder, AH; Öztürk, B; Sezer, E | 1 |
| Dixit, J; Gupta, D; Gupta, N; Gupta, S; Jyani, G; Kalaiyarasi, JP; Kataki, A; Krishnamurthy, MN; Kumar, L; Malhotra, P; Malik, PS; Mathew, A; Mehra, N; Prinja, S; Rajsekhar, K; Roy, PS; Singh, A | 1 |
| Higashi, T; Mase, K; Mizutani, M; Moriya, T; Ozawa, K; Takagi, S; Takei, S; Takeshita, A; Yokoyama, M | 1 |
| Agrawal, KU; Barke, MR; Shields, CL | 1 |
| Haddad, N; Huang, CS; Im, YH; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; van Hal, G; Zhang, W | 1 |
| Atake, Y; Bun, A; Fujimoto, Y; Fukui, R; Hattori, A; Higuchi, T; Imamura, M; Kanaoka, H; Miyoshi, Y; Murase, K; Nagahashi, M; Natori, K; Ozawa, H; Takatsuka, Y | 1 |
| Coutinho, A; Cui, ZL; Karuturi, M; Lokhandwala, T; Lunacsek, O; Ring, A; Rybowski, S; Sapunar, F; Sheffield, KM; Smyth, EN; Willey, J | 1 |
| Fakhouri, W; Faris, LH; Haro, JM; Kawaguchi, T; Novick, D; Nozawa, K; Onishi, M; Ozaki, Y; Takano, T; Tanizawa, Y; Terada, M; Tsurutani, J | 1 |
| Chu, T; Li, B; Li, S; Lu, Z; Nie, G; Qi, F; Song, Z; Sukumar, S; Wang, M; Wei, J; Wu, S; Xu, J; Zhang, C; Zhu, F | 1 |
14 review(s) available for fulvestrant and alpha-aminopyridine
| Article | Year |
|---|---|
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Treatment for the endocrine resistant breast cancer: Current options and future perspectives.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Morpholines; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction | 2017 |
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinases; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Triazoles | 2017 |
Abemaciclib: First Global Approval.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinases; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; United States; United States Food and Drug Administration | 2017 |
Abemaciclib for the treatment of breast cancer.
Topics: Aminopyridines; Benzimidazoles; Biomarkers; Brain Neoplasms; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Humans; Neoplasm Staging; Prognosis | 2018 |
Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Staging; Piperazines; Purines; Pyridines; Receptor, ErbB-2 | 2019 |
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Topics: Aminopyridines; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; ErbB Receptors; Everolimus; Female; Fulvestrant; Humans; Network Meta-Analysis; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; TOR Serine-Threonine Kinases | 2019 |
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Piperazines; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Japan; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2019 |
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
Topics: Alopecia; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Fulvestrant; Germany; Humans; Incidence; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Survival Rate; Tamoxifen | 2020 |
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cell Cycle Checkpoints; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Protein Kinase Inhibitors; Quality of Life | 2020 |
Ribociclib plus fulvestrant in the treatment of breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Fulvestrant; Humans; Progression-Free Survival; Purines; Randomized Controlled Trials as Topic; Survival Rate | 2021 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
20 trial(s) available for fulvestrant and alpha-aminopyridine
| Article | Year |
|---|---|
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Eruptions; Estradiol; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Retreatment; Signal Transduction; Survival Rate | 2017 |
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2017 |
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2018 |
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Progression-Free Survival; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Postmenopause; Survival Analysis | 2018 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Tamoxifen; Young Adult | 2019 |
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2020 |
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Topics: Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; Benzimidazoles; Brazil; Breast Neoplasms; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Humans; Middle Aged; North America; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Signal Transduction; Time Factors; Trastuzumab | 2020 |
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidazoles; Body Mass Index; Breast Neoplasms; Confidence Intervals; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neutropenia; Obesity; Odds Ratio; Overweight; Placebos; Progression-Free Survival; Thinness; Weight Loss | 2021 |
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Health Status; Humans; Kaplan-Meier Estimate; Middle Aged; Patient Reported Outcome Measures; Progression-Free Survival; Proportional Hazards Models; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Topics: Age Factors; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2021 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome | 2021 |
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Double-Blind Method; Female; Fulvestrant; Humans; Japan; Middle Aged; Quality of Life; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2021 |
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Topics: Adolescent; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2021 |
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Premenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2021 |
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Postmenopause; Purines | 2022 |
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Male; Mutation; Receptor, ErbB-2 | 2022 |
Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; East Asian People; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2023 |
36 other study(ies) available for fulvestrant and alpha-aminopyridine
| Article | Year |
|---|---|
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Estradiol; Estrogens; Everolimus; Female; Fulvestrant; Humans; Imidazoles; Morpholines; Mutation; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2011 |
Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Pathology, Molecular; Piperazines; Precision Medicine; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab | 2016 |
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Postmenopause; PTEN Phosphohydrolase; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2016 |
PI3K Inhibitor Improves PFS in BELLE-2 Trial.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Congresses as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Treatment Outcome | 2016 |
Benefit Mixed with Caution for Buparlisib.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Morpholines; Postmenopause; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2017 |
Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.
Topics: Aminopyridines; Ataxia Telangiectasia Mutated Proteins; Cyclin-Dependent Kinases; Drug Design; Estradiol; Fulvestrant; Imatinib Mesylate; Piperazines; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Sulfoxides; Vardenafil Dihydrochloride | 2017 |
Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Embarrassment; Female; Fulvestrant; Humans | 2017 |
[CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA].
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases | 2018 |
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; MCF-7 Cells; Mice; Mutation; Naphthalenes; Piperazines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Quinolines; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Fulvestrant; Humans; Japan; Middle Aged; Patient Preference; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Socioeconomic Factors; Surveys and Questionnaires | 2019 |
Abemaciclib plus fulvestrant for breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2019 |
CDK4/6 inhibitors prolong OS.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Fulvestrant; Humans; Receptor, ErbB-2 | 2019 |
CDK4/6 inhibition in HER2-positive breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Trastuzumab | 2020 |
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2 | 2020 |
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2 | 2020 |
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2 | 2020 |
Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Topics: Aminopyridines; Breast Neoplasms; Fulvestrant; Humans; Purines | 2020 |
Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply.
Topics: Aminopyridines; Breast Neoplasms; Fulvestrant; Humans; Purines | 2020 |
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Purines; Receptors, Estrogen; Thiazoles | 2021 |
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2021 |
[Locally Advanced Breast Cancer Successfully Treated with Abemaciclib and Fulvestrant-A Case Report].
Topics: Aged; Aminopyridines; Axilla; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lymph Node Excision; Lymph Nodes; Mastectomy; Neoplasm Recurrence, Local | 2020 |
[A Case of Palbociclib plus Fulvestrant‒Resistant Metastatic Breast Cancer That Responded to Abemaciclib plus Fulvestrant].
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Piperazines; Pyridines | 2021 |
Fatal acute hepatic failure secondary to thrombotic portal venopathy after commencing abemaciclib and fulvestrant treatment for advanced breast carcinoma: a unique autopsy finding.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Liver Failure, Acute; Receptor, ErbB-2 | 2021 |
[A Case of Hormone Receptor‒Positive HER2‒Negative Advanced/Recurrent Breast Cancer with 1.5 Years Withdrawal Period of Palbociclib Showed a Good Response Treated by Abemaciclib and Fulvestrant].
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyridines | 2021 |
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Delivery of Health Care; Female; Fulvestrant; Humans; Postmenopause; Purines; Receptor, ErbB-2 | 2021 |
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Benzimidazoles; Breast Neoplasms; Drug Combinations; Female; Fulvestrant; Humans; Neoplasm Staging; Progression-Free Survival; Receptor, ErbB-2; Treatment Outcome | 2021 |
Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fatal Outcome; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Peritoneal Neoplasms | 2021 |
Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report.
Topics: Acidosis, Lactic; Aminopyridines; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Metformin; Middle Aged; Purines; Renal Insufficiency | 2022 |
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Letrozole; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies | 2022 |
Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Paclitaxel; Piperazines; Postmenopause; Purines; Pyridines | 2022 |
[A Case of Postoperative Pulmonary Metastasis of Breast Cancer with Complete Response by Abemaciclib plus Fulvestrant Therapy].
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lung Neoplasms; Mastectomy; Neoplasm Recurrence, Local | 2022 |
Abemaciclib and Fulvestrant for Bilateral Choroidal Metastasis From Breast Carcinoma.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans | 2022 |
Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Topics: Aminopyridines; Benzimidazoles; Biomarkers; Breast Neoplasms; C-Reactive Protein; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Lymphocyte Count; Lymphocytes; Prognosis; Protein Kinase Inhibitors; Receptors, Estrogen; Retrospective Studies | 2022 |
Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Male; Receptor, ErbB-2; Retrospective Studies | 2023 |
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Japan; Middle Aged; Receptor, ErbB-2 | 2023 |
Nanoparticle-Based Combination Therapy Enhances Fulvestrant Efficacy and Overcomes Tumor Resistance in ER-Positive Breast Cancer.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Fulvestrant; Mice; Neoplasms; Receptors, Estrogen; Swine | 2023 |